Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Abivax will report H1 earnings Sept. 21; analysts expect a $1.08 loss/share and $1.86M revenue.
Stocks · News reference
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
https://www.lalettre.fr/fr/english-corner/2026/07/17/biotech-abivax-re-engages-investment-bank-centerview-for-big-pharma-takeover-talks,110842674-gra
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiate: Buy—Abivax ($155), Amer Sports ($42) and more
Goldman Sachs Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $155
Goldman Sachs analyst Rajan Sharma initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $155.
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
Transcript: AstraZeneca Q2 2026 Earnings Conference Call
On Monday, AstraZeneca (NASDAQ:AZN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.